Emplicure AB changes the Q1 reporting date to May 9
EMPLICURE AB CHANGES THE Q1 REPORTING DATE TO MAY 9
The Board of Directors of Emplicure AB has decided to change the date of the company's Q1 report to May 9 (previously 12 May).
For additional information, please contact
Håkan Engqvist
CEO
Phone: +46 702 569 500
Email: [email protected]
Erik Magnusson
CFO
Phone: +46 708 565 245
Email: [email protected]
Certified Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.
The following documents can be retrieved from beQuoted
PM-Emplicure Nytt-datum-Q1-ENG-2023-05-08.pdf
Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com